167 related articles for article (PubMed ID: 22262773)
21. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
[TBL] [Abstract][Full Text] [Related]
22. Hereditary erythrocytosis, thrombocytosis and neutrophilia.
Hong WJ; Gotlib J
Best Pract Res Clin Haematol; 2014 Jun; 27(2):95-106. PubMed ID: 25189721
[TBL] [Abstract][Full Text] [Related]
23. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
24. Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Broséus J; Park JH; Carillo S; Hermouet S; Girodon F
Blood; 2014 Dec; 124(26):3964-6. PubMed ID: 25305205
[TBL] [Abstract][Full Text] [Related]
25. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.
Ianotto JC; Curto-Garcia N; Lauermanova M; Radia D; Kiladjian JJ; Harrison CN
Haematologica; 2019 Aug; 104(8):1580-1588. PubMed ID: 30679326
[TBL] [Abstract][Full Text] [Related]
26. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
27. New advances in the pathogenesis and therapy of essential thrombocythemia.
Levine RL; Heaney M
Hematology Am Soc Hematol Educ Program; 2008; ():76-82. PubMed ID: 19074062
[TBL] [Abstract][Full Text] [Related]
28. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
29. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
[TBL] [Abstract][Full Text] [Related]
30. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
31. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A
Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
[TBL] [Abstract][Full Text] [Related]
32. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
33. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
Rudzki Z; Sacha T; Stój A; Czekalska S; Wójcik M; Skotnicki AB; Grabowska B; Zduńczyk A; Okoń K; Stachura J
Int J Hematol; 2007 Aug; 86(2):130-6. PubMed ID: 17875526
[TBL] [Abstract][Full Text] [Related]
34. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
[TBL] [Abstract][Full Text] [Related]
35. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O; Levine RL
Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
[TBL] [Abstract][Full Text] [Related]
36. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
37. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis.
Teofili L; Giona F; Torti L; Cenci T; Ricerca BM; Rumi C; Nunes V; Foà R; Leone G; Martini M; Larocca LM
Haematologica; 2010 Jan; 95(1):65-70. PubMed ID: 19713221
[TBL] [Abstract][Full Text] [Related]
38. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
39. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
[TBL] [Abstract][Full Text] [Related]
40. Germline MPL mutations may be a rare cause of "triple-negative" thrombocytosis.
Borsani O; Pietra D; Casetti IC; Vanni D; Riccaboni G; Catricalà S; Grazia B; Boveri E; Arcaini L; Rumi E
Exp Hematol; 2024 Jan; 129():104127. PubMed ID: 37939832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
